» Articles » PMID: 18082662

Subject and Clinician Experience with the Levonorgestrel-releasing Intrauterine System

Overview
Journal Contraception
Publisher Elsevier
Date 2007 Dec 18
PMID 18082662
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Because use of intrauterine contraception is now expanding, this article reports early US clinical experience with the levonorgestrel-releasing intrauterine system (LNG IUS) and assesses subjects' and clinicians' judgment of the adequacy of product information and the overall level of product satisfaction in order to provide insight to new providers of the LNG IUS.

Study Design: Multicenter, open-label, uncontrolled, Phase IIIb study. Investigators had no prior experience with the LNG IUS. Subjects and investigators completed surveys and questionnaires at 3, 6 and 12 months.

Results: A total of 509 women, aged 18 to 45 years, were enrolled in this study between July 2000 and June 2002, and 506 (99.4%) received a LNG IUS after the first (488/506, 95.9%) or second (18/20, 90%) insertion attempt. Insertion was rated as "easy" by 91.8% of investigators. Continuation rate at 12 months was 79%. Primary reasons for premature discontinuation were expulsion (4.5%) and menstrual cycle problems (3.8%). Most subjects (84.5%) indicated a high level of satisfaction with the LNG IUS.

Conclusion: Over 95% of women had successful insertions of the LNG IUS at first attempt, and less than 1% were unsuccessful after two attempts. Both clinicians and subjects were highly satisfied with product information and their experience with the LNG IUS. One-year continuation rates were comparable to those of other reversible methods.

Citing Articles

Comparing options for females seeking permanent contraception in high resource countries: a systematic review.

Gormley R, Vickers B, Cheng B, Norman W Reprod Health. 2021; 18(1):154.

PMID: 34284794 PMC: 8290533. DOI: 10.1186/s12978-021-01201-z.


There might be blood: a scoping review on women's responses to contraceptive-induced menstrual bleeding changes.

Polis C, Hussain R, Berry A Reprod Health. 2018; 15(1):114.

PMID: 29940996 PMC: 6020216. DOI: 10.1186/s12978-018-0561-0.


Complications and continuation rates associated with 2 types of long-acting contraception.

Berenson A, Tan A, Hirth J Am J Obstet Gynecol. 2015; 212(6):761.e1-8.

PMID: 25555662 PMC: 4457706. DOI: 10.1016/j.ajog.2014.12.028.


Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use.

Grunloh D, Casner T, Secura G, Peipert J, Madden T Obstet Gynecol. 2013; 122(6):1214-21.

PMID: 24201685 PMC: 4051392. DOI: 10.1097/01.AOG.0000435452.86108.59.


LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial.

Abu Hashim H, Zayed A, Ghayaty E, El Rakhawy M J Gynecol Oncol. 2013; 24(2):128-34.

PMID: 23653829 PMC: 3644688. DOI: 10.3802/jgo.2013.24.2.128.